Sunstone Life Science Ventures
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Private Equity, Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth
Geographical Focus
United States, United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Ireland, Austria, Netherlands, Hungary, Portugal, Sweden, Belgium, Norway, Finland, Poland, Czech Republic, Romania, Bulgaria
Industries Focus
- Healthcare
- Life Sciences
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Regenerative Medicine
- Oncology
- Neurology
- Cardiology
- Endocrinology
- Infectious Diseases
- Immuno-Oncology
- Women's Health
- Rare Diseases
- Healthcare IT
- Orthopedics
- Cell Therapy
- Gene Therapy
- Medical Imaging
- Medical Robotics
Investment Size:
1,500,000 to 3,000,000 USD
Investor Details Founded: 2007
Sunstone Life Science Ventures is an independent European venture capital firm founded in 2007, focusing on developing and expanding early-stage life science companies with strong potential to achieve global success. The firm manages approximately €500 million in assets and has invested in over 45 companies across pharmaceuticals, medical technologies, and diagnostics, achieving more than 20 successful IPOs and large M&A transactions.
The firm's investment strategy centers on novel therapeutics with the potential to improve patient care and treatment. Sunstone typically invests in companies raising Series A or B rounds, emphasizing strong scientific rationale and attractive business cases. Geographically, the firm focuses on Europe, particularly large life science hubs, and has made investments in Denmark, Finland, Germany, Sweden, the United Kingdom, and the United States.
Sunstone's team comprises industry experts with combined entrepreneurial, operational, and financial experience. They provide comprehensive support to portfolio companies, including strategic guidance, operational optimization, regulatory navigation, and market access planning. This hands-on approach has established Sunstone as a value-added partner for emerging biotech companies navigating the complex path from discovery to commercialization.
Requirements
- Focus on novel therapeutics
- Strong potential for global success
- Early-stage companies
- European market emphasis
- Strong scientific rationale
- Attractive business case
- Potential for global success
- Focus on early-stage life science companies
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Forendo Pharma
- Synendos Therapeutics
- STipe Therapeutics
- Rigontec
- Prexton Therapeutics
- Arcoma AB
- IO Biotech
- OxThera
- Antargia
- Adenium Biotech
- Minervax
- Galecto Biotech
- Alligator Biosciences
- Zeal & Revolutionary Health Solutions
- Vaximm
- Orphazyme
- Ascella Pharma
- Nuevolution
- Symphogen
- Evolva
- Resalis Therapeutics
- Teitur Trophics
- Rewind Therapeutics
- Forendo OY
- Corti
Mentioned In
-
$49.95
-
$24.95
-
$19.95
-
$19.95
-
$24.95
-
$99.00
Claim this Investor
Are you an official representative of Sunstone Life Science Ventures?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim